Open AccessTreatment of hyperthyroidism in pregnancy
Author(s) -
Sherif Ibrahim H.,
Oyan Win Tin,
Bosairi Soad,
Carrascal Sylvia Moran
Publication year - 1991
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349109007160
Subject(s) - carbimazole , medicine , pregnancy , propranolol , abortion , antithyroid agent , obstetrics , confusion , group b , gynecology , fetus , pediatrics , surgery , graves' disease , thyroid , biology , psychoanalysis , genetics , psychology
One hundred and five consecutive pregnancies in 79 women affected by hyperthyroidism were observed during an 8‐year period. AH had received treatment either with carbimazole alone (Group I) or with the combination of carbimazole and propranolol (Group II). There were 72 pregnancies in Group I, 33 in Group II. Seventy‐five pregnancies occurred whilst the mother was receiving antithyroid therapy and in the other 30 the diagnosis of hyperthyroidism was made following conception. The total fetal loss was 17.1%, with a spontaneous abortion rate of 5.5% in Group I and 24.2% in Group II. No congenital malformation or maternal deaths occurred. Carbimazole is safe and effective during pregnancy. Adding propranolol offers no further advantage and may indeed be detrimental.